-
Mashup Score: 4OnlineFirst - 17 hour(s) ago
This site uses cookies. By continuing to use our website, you are agreeing to our privacy
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6A Pan-Cancer Metastatic Microbiome Atlas Is Generated - 2 day(s) ago
Major Finding: A pan-cancer resource was developed that identifies the presence and relevance of the metastatic microbiome. Approach: Multi-omic analyses were conducted on 4,160 metastatic tumors across 26 tissues to identify microbiome complexity. Impact: Characterization of the metastatic microbiome may help identify candidates for immunotherapy.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22
Major Finding: IDH-mutant low-grade gliomas that respond to IDH inhibition undergo lineage differentiation. Concept: Glioma cell fate is shifted towards differentiation and away from a proliferative progenitor state. Impact: This study uncovers a mechanism that may inform patient stratification strategies for glioma treatment.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
Lineage Differentiation Underlies #Glioma Response to IDH Inhibition, a summary of the study by @AvishaySpitzer, @GritschSimon, @M_Nomura, @KeithLigon5, D. Cahill, @MarioSuva, @TiroshLab et al. https://t.co/BaBrzdOaxN @WeizmannScience @MGHCancerCenter @DanaFarber @broadinstitute https://t.co/2zVPEn5nCC
-
-
Mashup Score: 6Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance - 2 day(s) ago
Summary:. Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro.See related article by Rosano et al., p. 866 (9).
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15
Major Finding: Nonmalignant BRCA1/BRCA2-mutant breast tissues exhibit markers of immune infiltration and exhaustion. Approach: A single-cell atlas of the human breast maps changes influenced by age, parity, and germline mutations. Impact: This study suggests a role for immunotherapy in the prevention of BRCA1/BRCA2-mutant breast cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Major Finding: Anti-TRBC1 chimeric antigen receptor T-cell activity is limited by fratricide by normal TRBC1+ T cells. Concept: Development of an anti-TRBC1 antibody drug conjugate (ADC) demonstrates activity in T-cell cancers. Impact: These results suggest that this anti-TRBC1 ADC could be an attractive therapeutic candidate for T-cell cancers.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35
Abstract. RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that induce BRAF V600 dimerization, and poor brain penetration. Next-generation pan-RAF dimer inhibitors are limited by narrow therapeutic index. PF-07799933 (ARRY-440) is a brain-penetrant, selective, pan-mutant BRAF inhibitor. PF-07799933 inhibited signaling in vitro, disrupted endogenous mutant-BRAF:wild-type-CRAF dimers, and spared wild-type ERK signaling. PF-07799933 ± binimetinib inhibited growth of mouse xenograft tumors driven by mutant BRAF that functions as dimers and by BRAF V600E with acquired resistance to current RAF inhibitors. We treated patients with treatment-refractory BRAF-mutant solid tumors in a first-in-human clinical trial (NCT05355701) that utilized a novel, flexible, pharmacokinetics-informed dose escalation design that allowed rapid achievement of PF-07799933 efficacious concentra
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Elizabeth McKenna: We have an opening on the Cancer Discovery team! / American Association for Cancer Research, cancer, Cancer Discovery team, Elizabeth
Source: oncodaily.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Paolo Tarantino: HER2 is about to change again - OncoDaily - 3 day(s) ago
Paolo Tarantino: HER2 is about to change again / AstraZeneca, Breast Cancer, cancer, Cancer Discovery, DESTINY-Breast06 Trial, Enhertu, HER2-low Breast
Source: oncodaily.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers - 3 day(s) ago
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has critical implications for the treatment of NRASG12C- or HRASG12C-mutant tumors.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
Stay up to date with the latest Cancer Discovery #OnlineFirst articles. https://t.co/89pelMXwx4 https://t.co/xV5L5rkR1i